Research programme: TRAIL receptor 2 agonists - Genmab

Drug Profile

Research programme: TRAIL receptor 2 agonists - Genmab

Alternative Names: Hx-DR5-01; Hx-DR5-01/05; Hx-DR5-05; iDD 004

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator iDD Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioma; Solid tumours

Most Recent Events

  • 13 Jul 2016 Pharmacodynamics data from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 18 Mar 2015 Genmab acquires TRAIL receptor 2 antagonists from iDD Biotech
  • 01 Jan 2015 Preclinical trials in Solid tumours and Glioma in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top